The risk of thromboembolic events with early intravenous 2‐ and 4‐g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double‐blind, placebo‐controlled, single‐center trial
Abstract
Screening for the risk of thromboembolism (TE) due to tranexamic acid (TXA) in patients with severe traumatic injury has not been performed in randomized clinical trials. Our objective was to determine if TXA dose was independently‐associated with thromboembolism.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 29, 2022
- Source ID
- 10.1111/trf.16962
Entities
People
- Amanda Staudt
- Andrew P Cap
- Anthony E. Pusateri
- Douglas Schuerer
- Grant Bochicchio
- Jerrold Levy
- Kelly Bochicchio
- Kimberly A Thomas
- Philip C Spinella
- Susan M Hastings
Organizations
- Duke University
- Geneva Foundation
- United States Army Institute of Surgical Research
- United States Department of Defense
- University of Pittsburgh
- Washington University in St. Louis